Fundraising Fox

Perseus Proteomics

5 known investors

ppmx.com ↗

Perseus Proteomics (PPMX) is a Japanese biotech company that uses proprietary antibody technology to develop new antibody-based drugs. It also provides antibody research support services and sells antibodies and reagents, including PTX3 measurement kits.

BiotechDeep TechHealthtech

Investors · 5

DBJ CapitalTokyo · $2.7M – $354M
Kyoto University Innovation CapitalKyoto
Newton BiocapitalBrussels
Nippon Venture CapitalTokyo · $1.5M – $269M
SMBC Venture CapitalTokyo · $2.3M – $269Mvia Hiroya Ota · inferred

In the news

Perseus Proteomics Narrows Loss as Sales Rise but Withholds Full-Year Outlook - TipRanks.comtipranks.com · Aug 2026Perseus Proteomics Overhauls Board, Taps New Director to Lead Business Development - TipRanks.comtipranks.com · May 2026Perseus Proteomics Wins AMED Grant to Advance PPMX-T003 for Rare Leukemia - TipRanks.comtipranks.com · Apr 2026Perseus Proteomics Books Subsidy Income but Suffers Asset Impairment in Q3 - TipRanks.comtipranks.com · Feb 2026Perseus Proteomics Partners with Eurus Therapeutics for Antibody Research - TipRanks.comtipranks.com · Dec 2025

Frequently asked questions

What does Perseus Proteomics do?
Perseus Proteomics (PPMX) is a Japanese biotech company that uses proprietary antibody technology to develop new antibody-based drugs. It also provides antibody research support services and sells antibodies and reagents, including PTX3 measurement kits.
Who are Perseus Proteomics's investors?
Perseus Proteomics's investors include DBJ Capital, Kyoto University Innovation Capital, Newton Biocapital, Nippon Venture Capital, SMBC Venture Capital.